Ionis Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Amount
Ionis Pharmaceuticals, Inc. (IONS) reported Effective Income Tax Rate Reconciliation, Tax Credit, Amount of $53.50 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCredits · last filed 2026-02-26
- Ionis Pharmaceuticals, Inc. effective income tax rate reconciliation, tax credit, amount for fiscal 2024 was $53.50M, a 20.31% decline from fiscal 2023.
- Ionis Pharmaceuticals, Inc. effective income tax rate reconciliation, tax credit, amount for fiscal 2023 was $67.13M, a 68.97% increase from fiscal 2022.
- Ionis Pharmaceuticals, Inc. effective income tax rate reconciliation, tax credit, amount for fiscal 2022 was $39.73M, a 71.26% increase from fiscal 2021.
- Ionis Pharmaceuticals, Inc. effective income tax rate reconciliation, tax credit, amount for fiscal 2021 was $23.20M, a 23.56% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Amount 12 month as first filed |
|---|---|---|
| 2024-12-31 | $53.50M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $67.13M 10-K · filed 2026-02-26 | |
| 2022-12-31 | $39.73M 10-K · filed 2025-02-19 | |
| 2021-12-31 | $23.20M 10-K · filed 2024-02-21 | |
| 2020-12-31 | $18.77M 10-K · filed 2023-02-22 | |
| 2019-12-31 | $22.30M 10-K · filed 2022-02-25 | |
| 2018-12-31 | $73.36M 10-K · filed 2021-02-24 | |
| 2017-12-31 | $32.77M 10-K · filed 2020-03-02 | |
| 2016-12-31 | $26.95M 10-K · filed 2019-03-01 | |
| 2015-12-31 | $41.28M 10-K · filed 2018-02-28 | |
| 2014-12-31 | $23.63M 10-K · filed 2017-03-01 | $23.52M 10-K · filed 2015-03-02 |
| 2013-12-31 | $15.84M 10-K · filed 2016-02-26 | |
| 2012-12-31 | -$806.00K 10-K · filed 2015-03-02 | |
| 2011-12-31 | $4.20M 10-K · filed 2014-03-03 | |
| 2010-12-31 | $3.17M 10-K · filed 2013-02-28 | |
| 2009-12-31 | -$3.40M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |